Zostavax shortage due to unexpected popularity

Reports have emerged two weeks after the shingles vaccine was added to the National Immunisation Program Zostavax is Australia’s only vaccine to protect against shingles and postherpetic neuralgia, and on 1 November was added to the National Immunisation Program for people aged 70-79. Supplier Seqirus has confirmed that due to the vaccine's unexpected popularity, it is temporarily experiencing